For example, in my early college research, I worked on means of overcoming penicillin beta-lactamase mechanisms of penicillin resistance. ❋ Unknown (2009)
Antibiotics such as penicillin are called, collectively, beta-lactams, and enzymes that break down these antibiotics and confer drug resistance are called beta-lactamases, which is why the term beta-lactamase may pop up in this blog entry from time to time. ❋ Unknown (2007)
This is found to cause complete loss of function in vivo for two unrelated monomeric enzymes: barnase a bacterial RNase and TEM-1 beta-lactamase. ❋ Unknown (2005)
Using these simplifications, the difficulty of specifying a working beta-lactamase domain is assessed here. ❋ Unknown (2005)
NXL 104 is the last, the boldest beta-lactamase inhibitor now in development in clinical trials. ❋ Unknown (2011)
NXL 104 is a compound that inhibits several classes of bacterial enzymes called beta-lactamase that break down and activate beta-lactam antibiotics such as: Cephalosporin, a class to which ceftaroline belongs; penicillins; and carbapenems, making the pathogens producing these enzymes resistant to these antibiotics. ❋ Unknown (2011)
K. pneumoniae, including extended-spectrum beta-lactamase (ESBL) and multidrug-resistant (MDR) strains. ❋ Unknown (2011)
The gene for NDM-1 is one member of a large gene family that encodes beta-lactamase enzymes called carbapenemases. ❋ Unknown (2011)
Forest licensed Novexel, a French biotech company, the rights for North America for NXL 104, a beta-lactamase inhibitor for use in combination with ceftaroline. ❋ Unknown (2011)
ESBL extended-spectrum beta-lactamase producing E.coli are strains of E.coli that are resistant to antibiotics, making them difficult to treat. ❋ Telegraph Staff (2011)
E. coli, Acinetobacter and Klebsiella - that cause common and formidable hospital-acquired infections; 168, or 70 percent, of those were multi-drug resistant, and 58, or 24 percent, were ESBL extended-spectrum beta-lactamase producers, meaning they could only be treated by one remaining class of drugs. ❋ Maryn McKenna (2011)
It overcomes bacterial resistance by several mechanisms and is not easily destroyed by bacterial beta-lactamase enzymes, such as extended-spectrum beta-lactamases (ESBLs), carbapenemases and the recently characterized New Delhi metallo-beta-lactamase 1 (NDM-1), which cause resistance against many currently marketed antibiotics. ❋ Unknown (2011)
Chronically, no other beta-lactamase inhibitor available on the market can do better. ❋ Unknown (2011)
Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase. ❋ Chakrit Sawasdidoln Et Al. (2010)
AmpC beta-lactamase was overexpressed in 11.9% of P. aeruginosa isolates. ❋ Unknown (2010)
M. tuberculosis beta-lactamase discovery, but Blanchard thought it would be an attractive therapeutic target, considering several beta-lactamase inhibitors had been developed for other bacteria. ❋ Unknown (2010)
While M. tuberculosis was resistant to most beta-lactamase inhibitors, Blanchard's group found that the drug clavulanate was effective in shutting down the TB enzyme. ❋ Unknown (2010)
"When the M. tuberculosis genome was sequenced a few years ago, the presence of this beta-lactamase enzyme was discovered," Blanchard says, "which was surprising since beta-lactams have never been systematically used to treat TB." ❋ Unknown (2010)
Yep, the beta-lactamase inhibitor that's given as part of ❋ Derek Lowe (2010)
Pseudomonas aeruginosa due to chromosomal beta-lactamase. ❋ Chakrit Sawasdidoln Et Al. (2010)
